CA2265929A1 - A process for purifying apolipoproteins and a composition for use in the process - Google Patents

A process for purifying apolipoproteins and a composition for use in the process Download PDF

Info

Publication number: CA2265929A1
Authority: CA; Canada
Prior art keywords: polymeric material; surfactant; process according; hydrophobic; aqueous solution
Prior art date: 1996-09-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002265929A

Other languages

English (en)

French (fr)

Inventor

Hans Ageland

Lena Nystrom

Josefine Persson

Folke Tjerneld

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Health AB

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-11

Filing date

1997-09-08

Publication date

1998-03-19

1996-09-11 Priority claimed from SE9603304A external-priority patent/SE9603304D0/xx

1997-09-08 Application filed by Individual filed Critical Individual

1998-03-19 Publication of CA2265929A1 publication Critical patent/CA2265929A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 80
230000008569 process Effects 0.000 title claims abstract description 53
239000000203 mixture Substances 0.000 title claims abstract description 47
108010071619 Apolipoproteins Proteins 0.000 title claims abstract description 12
102000007592 Apolipoproteins Human genes 0.000 title claims abstract description 12
239000000463 material Substances 0.000 claims abstract description 139
239000004094 surface-active agent Substances 0.000 claims abstract description 108
150000001875 compounds Chemical class 0.000 claims abstract description 75
230000002209 hydrophobic effect Effects 0.000 claims abstract description 70
239000007864 aqueous solution Substances 0.000 claims abstract description 51
101710095339 Apolipoprotein E Proteins 0.000 claims abstract description 28
102100029470 Apolipoprotein E Human genes 0.000 claims abstract description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
238000002156 mixing Methods 0.000 claims abstract description 17
201000001320 Atherosclerosis Diseases 0.000 claims abstract description 15
239000007858 starting material Substances 0.000 claims abstract description 13
208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 8
206010040047 Sepsis Diseases 0.000 claims abstract description 8
230000002093 peripheral effect Effects 0.000 claims abstract description 8
238000004519 manufacturing process Methods 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims abstract description 4
-1 hydroxybutyl Chemical group 0.000 claims description 31
229920000642 polymer Polymers 0.000 claims description 29
229920002472 Starch Polymers 0.000 claims description 23
235000019698 starch Nutrition 0.000 claims description 23
239000010695 polyglycol Substances 0.000 claims description 21
229920001577 copolymer Polymers 0.000 claims description 17
239000008107 starch Substances 0.000 claims description 14
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 12
238000004064 recycling Methods 0.000 claims description 12
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
102000004196 processed proteins & peptides Human genes 0.000 claims description 10
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 9
239000002736 nonionic surfactant Substances 0.000 claims description 9
229920001184 polypeptide Polymers 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 8
229920002307 Dextran Polymers 0.000 claims description 7
108020004511 Recombinant DNA Proteins 0.000 claims description 7
229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 7
235000013828 hydroxypropyl starch Nutrition 0.000 claims description 7
108010059886 Apolipoprotein A-I Proteins 0.000 claims description 6
102000005666 Apolipoprotein A-I Human genes 0.000 claims description 6
229920001400 block copolymer Polymers 0.000 claims description 6
229920002678 cellulose Polymers 0.000 claims description 6
239000001913 cellulose Substances 0.000 claims description 6
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 6
238000010438 heat treatment Methods 0.000 claims description 6
239000001341 hydroxy propyl starch Substances 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
239000003945 anionic surfactant Substances 0.000 claims description 5
229920005604 random copolymer Polymers 0.000 claims description 5
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 4
239000004373 Pullulan Substances 0.000 claims description 4
229920001218 Pullulan Polymers 0.000 claims description 4
150000005215 alkyl ethers Chemical class 0.000 claims description 4
239000003093 cationic surfactant Substances 0.000 claims description 4
229940050526 hydroxyethylstarch Drugs 0.000 claims description 4
150000002632 lipids Chemical class 0.000 claims description 4
229920000570 polyether Polymers 0.000 claims description 4
229920000151 polyglycol Polymers 0.000 claims description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
235000019423 pullulan Nutrition 0.000 claims description 4
229920002554 vinyl polymer Polymers 0.000 claims description 4
239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
230000015556 catabolic process Effects 0.000 claims description 3
238000006731 degradation reaction Methods 0.000 claims description 3
150000002170 ethers Chemical class 0.000 claims description 3
229930182470 glycoside Natural products 0.000 claims description 3
239000000693 micelle Substances 0.000 claims description 3
125000005702 oxyalkylene group Chemical group 0.000 claims description 3
229920001515 polyalkylene glycol Polymers 0.000 claims description 3
229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
239000002158 endotoxin Substances 0.000 claims description 2
229920006008 lipopolysaccharide Polymers 0.000 claims description 2
239000012528 membrane Substances 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims 2
230000001376 precipitating effect Effects 0.000 claims 1
238000000746 purification Methods 0.000 abstract description 29
239000012071 phase Substances 0.000 description 112
238000005191 phase separation Methods 0.000 description 36
102000004169 proteins and genes Human genes 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 29
235000018102 proteins Nutrition 0.000 description 27
238000000926 separation method Methods 0.000 description 27
238000000638 solvent extraction Methods 0.000 description 20
239000000243 solution Substances 0.000 description 19
230000001747 exhibiting effect Effects 0.000 description 17
150000003839 salts Chemical class 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 12
239000000047 product Substances 0.000 description 12
102000015779 HDL Lipoproteins Human genes 0.000 description 11
108010010234 HDL Lipoproteins Proteins 0.000 description 11
238000000855 fermentation Methods 0.000 description 10
230000004151 fermentation Effects 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
102000004895 Lipoproteins Human genes 0.000 description 8
108090001030 Lipoproteins Proteins 0.000 description 8
239000002202 Polyethylene glycol Substances 0.000 description 8
229940117927 ethylene oxide Drugs 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000000694 effects Effects 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
235000010633 broth Nutrition 0.000 description 6
239000003599 detergent Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
230000008901 benefit Effects 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
239000000539 dimer Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
229920001451 polypropylene glycol Polymers 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
230000009102 absorption Effects 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
239000012620 biological material Substances 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
239000000356 contaminant Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
238000010587 phase diagram Methods 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920000896 Ethulose Polymers 0.000 description 2
239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920004929 Triton X-114 Polymers 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical class C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
229960003964 deoxycholic acid Drugs 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
230000003028 elevating effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
150000002433 hydrophilic molecules Chemical class 0.000 description 2
238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
229910017053 inorganic salt Inorganic materials 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000005192 partition Methods 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Chemical class OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
108010027004 Apolipoproteins A Proteins 0.000 description 1
102000018619 Apolipoproteins A Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
239000004380 Cholic acid Chemical class 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 1
101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
241000283986 Lepus Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940106135 cellulose Drugs 0.000 description 1
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical class CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
229960004830 cetylpyridinium Drugs 0.000 description 1
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
NAPSCFZYZVSQHF-UHFFFAOYSA-N dimantine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 description 1
OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
150000002061 ecdysteroids Chemical class 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000053020 human ApoE Human genes 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical group [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920002114 octoxynol-9 Polymers 0.000 description 1
238000005457 optimization Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000004141 reverse cholesterol transport Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940032330 sulfuric acid Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000002277 temperature effect Effects 0.000 description 1
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-O tributylazanium Chemical compound CCCC[NH+](CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-O 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002265929A 1996-09-11 1997-09-08 A process for purifying apolipoproteins and a composition for use in the process Abandoned CA2265929A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
SE9603304A SE9603304D0 (sv)	1996-09-11	1996-09-11	Process for purifying a compound
SE9603304-8		1996-09-11
US2673996P	1996-09-26	1996-09-26
US60/026,739		1996-09-26
PCT/SE1997/001502 WO1998011127A1 (en)	1996-09-11	1997-09-08	A process for purifying apolipoproteins and a composition for use in the process

Publications (1)

Publication Number	Publication Date
CA2265929A1 true CA2265929A1 (en)	1998-03-19

Family

ID=26662746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002265929A Abandoned CA2265929A1 (en)	1996-09-11	1997-09-08	A process for purifying apolipoproteins and a composition for use in the process

Country Status (12)

Country	Link
EP (1)	EP0954524B1 (de)
JP (1)	JP2001500154A (de)
AT (1)	ATE236925T1 (de)
AU (1)	AU729536B2 (de)
CA (1)	CA2265929A1 (de)
DE (1)	DE69720786T2 (de)
DK (1)	DK0954524T3 (de)
ES (1)	ES2197361T3 (de)
NO (1)	NO323217B1 (de)
NZ (1)	NZ334589A (de)
PT (1)	PT954524E (de)
WO (1)	WO1998011127A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7205280B2 (en) *	1998-03-11	2007-04-17	Cognosci, Inc.	Methods of suppressing microglial activation
ATE266672T1 (de) *	1998-12-30	2004-05-15	Folke Tjerneld	Trennungsmethode unter verwendung von flüssig- flüssig partition
SE9904803D0 (sv) *	1999-12-27	1999-12-27	Amersham Pharm Biotech Ab	Method for the isolation of hydrophobic proteins
FR2827192B1 (fr) *	2001-07-13	2004-06-04	Cognis France Sa	Preparations contenant des agents tensio-actifs non ioniques comme agents d'extraction
CN100357325C (zh) *	2005-10-23	2007-12-26	王贤理	一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒
WO2012024691A1 (en)	2010-08-20	2012-02-23	President And Fellows Of Harvard College	Multiphase systems for analysis of solid materials

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1229996B (it) *	1989-04-20	1991-09-20	Cesare Sirtori	Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
WO1993000443A1 (en) *	1991-06-26	1993-01-07	Bio-Technology General Corp.	Purification of recombinant apolipoprotein e from bacteria

1997
- 1997-09-08 AT AT97939315T patent/ATE236925T1/de not_active IP Right Cessation
- 1997-09-08 WO PCT/SE1997/001502 patent/WO1998011127A1/en not_active Ceased
- 1997-09-08 DE DE69720786T patent/DE69720786T2/de not_active Expired - Fee Related
- 1997-09-08 JP JP10513557A patent/JP2001500154A/ja not_active Withdrawn
- 1997-09-08 DK DK97939315T patent/DK0954524T3/da active
- 1997-09-08 AU AU41430/97A patent/AU729536B2/en not_active Ceased
- 1997-09-08 NZ NZ334589A patent/NZ334589A/xx unknown
- 1997-09-08 EP EP97939315A patent/EP0954524B1/de not_active Expired - Lifetime
- 1997-09-08 PT PT97939315T patent/PT954524E/pt unknown
- 1997-09-08 CA CA002265929A patent/CA2265929A1/en not_active Abandoned
- 1997-09-08 ES ES97939315T patent/ES2197361T3/es not_active Expired - Lifetime
1999
- 1999-03-11 NO NO19991208A patent/NO323217B1/no unknown

Also Published As

Publication number	Publication date
DK0954524T3 (da)	2003-08-04
DE69720786T2 (de)	2003-11-06
NZ334589A (en)	2000-07-28
NO991208D0 (no)	1999-03-11
ES2197361T3 (es)	2004-01-01
NO323217B1 (no)	2007-01-29
AU4143097A (en)	1998-04-02
EP0954524A1 (de)	1999-11-10
DE69720786D1 (de)	2003-05-15
NO991208L (no)	1999-05-11
PT954524E (pt)	2003-08-29
JP2001500154A (ja)	2001-01-09
EP0954524B1 (de)	2003-04-09
WO1998011127A1 (en)	1998-03-19
ATE236925T1 (de)	2003-04-15
AU729536B2 (en)	2001-02-01

Legal Events

Date	Code	Title	Description
2002-09-03	EEER	Examination request
2009-01-19	FZDE	Discontinued

Publication	Publication Date	Title
Meissner et al.	1974	Dissociation and reconstitution of functional sarcoplasmic reticulum vesicles
RU2311460C2 (ru)	2007-11-27	Способ очистки липопептида (варианты), антибиотическая композиция на основе очищенного липопептида (варианты)
US6559284B1 (en)	2003-05-06	Process for purifying a protein
US6107467A (en)	2000-08-22	Process for purifying a compound
JP3771935B2 (ja)	2006-05-10	水溶性血漿タンパク質の純化方法
IE66334B1 (en)	1995-12-27	Production of proteins in active forms
JPH04243899A (ja)	1992-08-31	第ｖｉｉｉ因子の精製およびこの方法で得られた第ｖｉｉｉ因子
CN106349387A (zh)	2017-01-25	一种从Cohn组分Ⅳ沉淀中纯化α1‑抗胰蛋白酶的方法
CA2265929A1 (en)	1998-03-19	A process for purifying apolipoproteins and a composition for use in the process
FI98642C (fi)	1997-07-25	Menetelmiä mikrobiologisesti tuotetun kymosiinin talteenottamiseksi
EP0295859B1 (de)	1994-11-17	Herstellung von Proteinen in aktiver Form
EP0934337B1 (de)	2007-12-19	Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma
EP0117470B1 (de)	1987-09-09	Verfahren zur Herstellung von Interferon (IFN-gamma) des Typs 26K und 21K
EP0422769B1 (de)	1997-04-09	Reinigung von Albumin
EP1720897B1 (de)	2010-03-31	Verfahren zur extraktion eines intrazellulären proteins aus einer fermentationsbrühe
Dooijewaard et al.	1978	Characterization of type-I NADH dehydrogenase. Polydispersity, molecular weight and polypeptide composition
AU4142997A (en)	1998-04-02	A process for purifying apolipoproteins and a composition for use in the proc ess
Steffens et al.	1990	Rapid purification of cytochrome c oxidase from Paracoccus denitrificans
JPS5939421B2 (ja)	1984-09-22	インシユリンの精製方法
AU2813295A (en)	1996-01-19	Filtration